Short answer
CRISPR Therapeutics AG (CRSP) filed an 8-K current report with the SEC on March 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Convertible notes sold via Rule 144A private placement to qualified institutional buyers: no public registration, limiting secondary market liquidity.
CRISPR Therapeutics AG 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Convertible notes sold via Rule 144A private placement to qualified institutional buyers: no public registration, limiting secondary market liquidity
- Purchase agreement dated March 10, 2026 between CRISPR Therapeutics and initial purchasers: conversion into common shares exempt under Securities Act Section 3(a)(9)
- Key risk: proceeds use is forward-looking and subject to material uncertainty per company's own cautionary language
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CRISPR Therapeutics AG 8-K filings
Get the next CRSP 8-K as it lands
Follow CRSP for push alerts, or ask the research agent what this filing means.